The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

U.S. drug maker Eli Lilly & Co. is slashing the prices of its popular diabetes and weight-loss drugs Mounjaro and Zepbound by ...

Eli Lilly's new obesity drug shows promising results in weight loss, surpassing its existing drug Zepbound, as competition in ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...

The steep monthly costs of GLP-1 medications have long been a major obstacle for many patients trying to find effective ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...

Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...